Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Non-melanoma Skin Cancer 2Skin Neoplasms 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lung Neoplasms 1Hand-Foot Syndrome 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × Diclofenac × Clear all
NCT00601640 2017-03-23

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

University of Arizona

Phase 2 Completed
184 enrolled 9 charts
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡